PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Doxylamine succinate/pyridoxine hydrochloride - Nausea and vomiting (pregnancy)

PAD Profile : Doxylamine succinate/pyridoxine hydrochloride - Nausea and vomiting (pregnancy)

Keywords :
morning sickness, nausea and vomiting in pregnancy
Brand Names Include :
Xonvea

Traffic Light Status

Status 1 of 1.

Status :
Green (see narrative)
Important
Formulations :
  • Gastro-resistant tablets
Important Information :
Not a preferred 1st-line option. Use only after failure of at least one established 1st-line treatment options
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
01 May 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands APC approved doxylamine with pyridoxine for use in nausea and vomiting in pregnancy, acknowledging that the drug is licensed for this indication.

However, it was agreed that it should only be considered after a trial of a more established drug (off-label cyclizine, promethazine, prochlorperazine or chlorpromazine).

The Surrey Heartlands APC agreed a traffic light status and place in therapy for drugs used to treat nausea and vomiting in pregnancy.

Visit  the Guideline Profile page for a full list of these drugs and to access the CKS guidelines for nasea & vomiting and pregnancy and the BUMPS website (Best Use of Medicines in Pregnancy).

Associated BNF Codes

04. Central Nervous System
04.06.00. Drugs used in nausea and vertigo
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More